We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals

210 hedge funds and large institutions have $604M invested in Supernus Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 86 increasing their positions, 56 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 23

54% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 56

13% more funds holding

Funds holding: 186210 (+24)

1% more call options, than puts

Call options by funds: $2.37M | Put options by funds: $2.35M

9% less capital invested

Capital invested by funds: $661M → $604M (-$56.9M)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
210
Holders Change
+24
Holders Change %
+12.9%
% of All Funds
5.49%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.08%
New
48
Increased
86
Reduced
56
Closed
23
Calls
$2.37M
Puts
$2.35M
Net Calls
+$17K
Net Calls Change
-$45K

SUPN Hedge Fund Activity: Q4 2015 in Review

210 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2015, worth a combined $604M — down 8.6% from $661M a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new SUPN positions and 23 closed out — a net gain of 25 holders — while 86 added to existing stakes and 56 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $14.1M. The largest seller was NEA Management Company, exiting entirely with an estimated $107M sold.

  • 210 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2015, up from 186 in Q3 2015.
  • Funds reported $604M of Supernus Pharmaceuticals stock for Q4 2015, down 8.6% quarter-over-quarter.
  • 48 funds opened new Supernus Pharmaceuticals positions in Q4 2015 and 23 closed out, a net change of +25 holders.
  • The largest Supernus Pharmaceuticals buyer in Q4 2015 was Acadian Asset Management, an estimated $14.1M added.
  • The largest Supernus Pharmaceuticals seller in Q4 2015 was NEA Management Company, an estimated $107M sold.

Based on aggregated 13F filings for Q4 2015.